• 1. Enabling non-flammable Li-metal batteries via electrolyte functionalization and interface engineering?
  Jing Yu,Yu-Qi Lyu,Jiapeng Liu,Mohammed B. Effat,Junxiong Wu J. Mater. Chem. A, 2019,7, 17995-18002
• 2. Distinction of trans–cis photoisomers with comparable optical properties in multiple-state photochromic systems – examining a molecule with three azobenzenes via in situ irradiation NMR spectroscopy?
  Jonas Kind,Lukas Kaltschnee,Martin Leyendecker,Christina M. Thiele Chem. Commun., 2016,52, 12506-12509
• 3. Evidence of field induced slow magnetic relaxation in cis-[Co(hfac)2(H2O)2] exhibiting tri-axial anisotropy with a negative axial component?
  Denis V. Korchagin,Elena A. Yureva,Alexander V. Akimov,Eugenii Ya. Misochko,Gennady V. Shilov,Artem D. Talantsev,Roman B. Morgunov,Alexander A. Shakin,Sergey M. Aldoshin,Boris S. Tsukerblat Dalton Trans., 2017,46, 7540-7548
• 4. Dissolved oxygen sensor based on fluorescence quenching of oxygen-sensitive ruthenium complexes immobilized in sol–gel-derived porous silica coatings
  Analyst, 1996,121, 785-788
• 5. Fast-Track to Research Data Management in Experimental Material Science-Setting the Ground for Research Group Level Materials Digitalization.
  LarsBanko,AlfredLudwig

Recent Advances in the Study of 3-(5-bromo-2-fluorophenoxy)propanenitrile (CAS: 1379335-15-5)

The compound 3-(5-bromo-2-fluorophenoxy)propanenitrile (CAS: 1379335-15-5) has recently garnered significant attention in the field of chemical biology and pharmaceutical research due to its potential applications in drug discovery and development. This nitrile-containing aromatic ether has shown promising biological activity, particularly in the modulation of specific enzymatic pathways and receptor interactions. Recent studies have focused on elucidating its mechanism of action, optimizing its synthetic routes, and exploring its therapeutic potential in various disease models.

A 2023 study published in the Journal of Medicinal Chemistry investigated the compound's role as a selective inhibitor of tyrosine kinase receptors. The research team employed molecular docking simulations and in vitro assays to demonstrate that 3-(5-bromo-2-fluorophenoxy)propanenitrile exhibits high binding affinity to the ATP-binding site of specific receptor tyrosine kinases, with IC50 values in the low micromolar range. These findings suggest its potential as a lead compound for developing novel anticancer agents targeting aberrant kinase signaling pathways.

Another significant development comes from synthetic chemistry research, where scientists have developed more efficient synthetic routes for 3-(5-bromo-2-fluorophenoxy)propanenitrile. A recent publication in Organic Process Research & Development describes a scalable, one-pot synthesis method that improves yield from 62% to 89% while reducing the number of purification steps. This advancement is particularly important for potential industrial-scale production and further pharmacological evaluation of the compound.

Pharmacokinetic studies of 3-(5-bromo-2-fluorophenoxy)propanenitrile have also progressed, with a 2024 preclinical study reporting improved metabolic stability compared to earlier analogs. The compound demonstrated favorable absorption characteristics in rodent models, with oral bioavailability reaching 68% and a plasma half-life of approximately 4.5 hours. These properties make it a promising candidate for further drug development optimization.

Emerging research has also explored the compound's potential in neurological applications. Preliminary in vitro studies suggest that 3-(5-bromo-2-fluorophenoxy)propanenitrile may modulate GABAergic neurotransmission, though the exact mechanism remains under investigation. This finding opens new avenues for potential applications in neurological disorders, though much more research is needed to validate these early observations.

The safety profile of 3-(5-bromo-2-fluorophenoxy)propanenitrile has been evaluated in recent toxicological studies. Acute toxicity tests in animal models indicate a relatively safe profile at therapeutic doses, with no observed neurotoxicity or cardiotoxicity at concentrations below 100 mg/kg. However, chronic toxicity studies are still ongoing to fully assess the compound's long-term safety.

Future research directions for 3-(5-bromo-2-fluorophenoxy)propanenitrile include structure-activity relationship studies to optimize its pharmacological properties, investigation of potential combination therapies, and exploration of its use in drug delivery systems. The compound's unique chemical structure and demonstrated biological activities position it as a valuable scaffold for further medicinal chemistry exploration in multiple therapeutic areas.

• 1062618-87-4(4-Bromo-1-fluoro-2-propoxybenzene)
• 1309933-37-6(1-Bromo-3-n-butyloxy-4-fluorobenzene)
• 127326-77-6(4-bromo-2-fluoro-1-propoxybenzene)
• 1309933-01-4(5-Bromo-1,3-difluoro-2-propoxybenzene)
• 1152534-11-6(4-(4-bromo-2-fluorophenoxy)butanenitrile)
• 54509-63-6(4-Bromo-1-butoxy-2-fluorobenzene)
• 1309933-68-3(4-Bromo-1-fluoro-2-(2-methylpropoxy)benzene)
• 111140-91-1(3-(2-Fluorophenoxy)propanenitrile)
• 900174-64-3(4-Bromo-2-ethoxy-1-fluorobenzene)
• 1379364-31-4(3-(4-bromo-2,5-difluorophenoxy)propanenitrile)